

Final Agenda October 23-24, 2024

MEETING OF THE ADVISORY COMMITTEE ON IMMUNIZATION PRACTICES (ACIP)

Centers for Disease Control and Prevention

Atlanta, Georgia 30329

October 23-24, 2024

Wednesday, October 23, 2024

8:00	Welcome & Introductions	Dr. Keipp Talbot (ACIP Chair) Dr. Melinda Wharton (ACIP Executive Secretary, CDC)
8:20	Pneumococcal Vaccines	
	Introduction	Dr. Jamie Loehr (ACIP, WG Chair)
	Economic Analysis and public health impact of PCV use for adults aged ≥ 50 years	Dr. Charles Stoecker (Tulane University)
	Summary of economic analyses of PCV use in adults aged ≥ 50 years	Dr. Andrew Leidner (CDC/NCIRD)
	Summary of WG Interpretation of EtR and policy options on PCV use in adults aged ≥ 50 years	Dr. Miwako Kobayashi (CDC/NCIRD)
	Clinical considerations for PCV use in adults	Dr. Miwako Kobayashi (CDC/NCIRD)
10:30	Break	
10:40	Influenza Vaccines	
	Introduction	Dr. Jamie Loehr (ACIP, WG Chair)
	Vaccine Effectiveness Update	Dr. Sascha Ellington (CDC/NCIRD)
	Influenza A/H5 update	Dr. Tom Shimabukuro (CDC/NCIRD)
	Influenza Vaccines VFC Resolution	Dr. Jeanne Santoli (CDC/NCIRD)
11:25	Chikungunya Vaccines	
	Introduction	Dr. Edwin Asturias (ACIP, WG Chair)
	Update on chikungunya and chikungunya vaccines	Dr. Susan Hills (CDC/NCEZID)
	Virus-like particle chikungunya vaccine	Dr. Victoria Jenkins (Bavarian Nordic)
	Work group interpretation of vaccine data	Dr. Susan Hills (CDC/NCEZID)
12:10	Break	
12:40	COVID-19 Vaccines	
	Introduction	Dr. Robert Schechter (ACIP, WG Chair)
	COVID-19 vaccine uptake and implementation	Dr. Georgina Peacock (CDC/NCIRD)
	COVID-19 epidemiology	Dr. Christopher Taylor (CDC/NCIRD)
	COVID-19 vaccine effectiveness	Dr. Ruth Link-Gelles (CDC/NCIRD)
	Economic analysis of an additional dose of the 2024-2025 COVID-19 vaccine	Dr. Lisa Prosser (University of Michigan)
	EtR	Ms. Lauren Roper (CDC/NCIRD)
	Clinical considerations	Dr. Lakshmi Panagiotakopoulos (CDC/NCIRD)
3:35	Break	
3:45	Public Comment	
4:05	<u>VOTES</u>	
	<u>Pneumococcal Vaccines</u>	Dr. Miwako Kobayashi (CDC/NCIRD)
	<u>Influenza Vaccines VFC</u>	Dr. Jeanne Santoli (CDC/NCIRD)
	<u>COVID-19 Vaccines</u>	Ms. Lauren Roper (CDC/NCIRD)
4:35	Respiratory Syncytial Virus (RSV) Vaccines - Maternal/Pediatric	
	Introduction	Dr. Helen Chu (ACIP, WG Chair)
	Safety and efficacy of clesrovimab	Dr. Anushua Sinha (Merck)
	Maternal RSV vaccine safety	Dr. Malini B. DeSilva (Health Partners Institute)
	Workgroup considerations	Ms. Danielle Moulia (CDC/NCIRD)
5:30	Recess	

Final Agenda October 23-24, 2024

Thursday, October 24, 2024

8:00	Welcome & Introductions	Dr. Keipp Talbot (ACIP Chair) Dr. Melinda Wharton (ACIP Executive Secretary, CDC)
8:10	Agency Updates	<i>CDC, CMS, FDA, HRSA, IHS, OIDP, NIH)</i>
8:30	Meningococcal Vaccines	
	Introduction	Dr. Jamie Loehr (ACIP, WG Chair)
	Economic analysis of GSK MenABCWY vaccine and comparison of GSK and CDC analyses	Dr. Xiaoyu Dong (CDC/NCIRD)
	GRADE/EtR for GSK MenABCWY vaccine	Dr. Sarah Schillie (CDC/NCIRD)
	Introduction to Bexsero interval and dosing label change	Dr. Sarah Schillie (CDC/NCIRD)
	EtR for Bexsero interval and dosing change	Dr. Sarah Schillie (CDC/NCIRD)
	Summary of work group considerations regarding Bexsero interval and dosing change	Dr. Sarah Schillie (CDC/NCIRD)
10:30	<i>Break</i>	
10:45	Respiratory Syncytial Virus (RSV) Vaccines - Adult	
	Introduction	Dr. Albert Shaw (ACIP, WG Chair)
	Moderna coadministration with high-dose influenza vaccine	TBD (Moderna)
	Pfizer immunogenicity in immunocompromised adults, coadministration with COVID-19 and high-dose influenza vaccines	Dr. Iona Munjal (Pfizer)
	GSK season 3 efficacy, immunogenicity in immunocompromised adults	Dr. Susan Gerber (GSK)
	FDA self-controlled case series GBS update	Dr. Patricia Lloyd (FDA)
	Work Group interpretations	Dr. Michael Melgar (CDC/NCIRD)
12:45	<i>Break</i>	
1:15	Immunization Schedules	
	Introduction to 2025 adult and child/adolescent immunization schedule	Dr. Sybil Cineas (ACIP, WG Chair)
	2025 child and adolescent schedule revisions	Dr. Nanda Issa (CDC/NCIRD)
	2025 adult schedule revisions	Dr. Patricia Wodi (CDC/NCIRD)
2:15	<i>Break</i>	
2:25	Public Comment	
2:45	<u>VOTES</u>	
	<u>Meningococcal Vaccines</u>	Dr. Sarah Schillie (CDC/NCIRD)
	<u>Meningococcal VFC</u>	Dr. Jeannie Santoli (CDC/NCIRD)
	<u>Immunization Schedules</u>	Dr. Patricia Wodi (CDC/NCIRD)
3:05	<i>Break</i>	
3:15	Human papillomavirus (HPV) Vaccines	
	Introduction	Dr. Oliver Brooks (ACIP, WG Chair)
	Introduction to policy consideration: reduced number of doses	Dr. Lauri Markowitz (CDC/NCIRD)
	Introduction to policy consideration: wording of the age for routine vaccination	Dr. Ruth Stefanos (CDC/NCIRD)
	Review of the literature on HPV vaccination at ages 9-10 to increase coverage	Dr. Sarah Brewer (CDC/NCIRD)
	Work group - next steps	Dr. Carla DeSisto (CDC/NCIRD)
4:30	Cytomegalovirus (CMV) Vaccine	
	Introduction: formation of the CMV vaccine workgroup	Dr. Denise Jamieson (ACIP, WG Chair)
4:40	Mpox Vaccine	
	Clade 1 Mpox Outbreak in Africa: Situational Update	Dr. Agam Rao (CDC/NCEZID)
5:00	Adjourn	

Final Agenda October 23-24, 2024

Acronyms

CDC	Centers for Disease Control and Prevention
CMS	Centers for Medicare and Medicaid Services
CORVD	Coronavirus and Other Respiratory Viruses Division
COVID-19	Coronavirus disease 2019
EtR	Evidence to Recommendations Framework
FDA	Food and Drug Administration
GRADE	Grading of Recommendations Assessment, Development and Evaluation
HRSA	Health Resources and Services Administration
HPV	Human papillomavirus
IHS	Indian Health Service
ISO	Immunization Safety Office
NCHHSTP	National Center for HIV, Hepatitis, STD and TB Prevention
NCIRD	National Center for Immunization & Respiratory Diseases
NCEZID	National Center for Emerging and Zoonotic Diseases
NIAID	National Institute of Allergy and Infectious Diseases
OIDP	Office of Infectious Disease and HIV/AIDS Policy
RSV	Respiratory Syncytial Virus (RSV)
SARS-CoV-2	Severe Acute Respiratory Syndrome Coronavirus 2
WG	Work Group
WHO	World Health Organization
VAERS	Vaccine Adverse Event Reporting System
VE	Vaccine Effectiveness
VFC	Vaccines for Children